Business, energy, technology, markets and global industry news from Business News Today

liquid biopsy

PharmaDeviceNews liquid biopsy
Representative image of circulating tumor cell analysis in a laboratory setting, illustrating how CTC enumeration is being explored to guide treatment escalation decisions in hormone receptor‑positive, HER2‑negative metastatic breast cancer following CDK4/6 inhibitor progression.
Medical Devices & Diagnostics

PACE trial: What Menarini’s biomarker data reveals about escalating treatment in metastatic breast cancer

Menarini Silicon Biosystems has reported new secondary analysis results from the PACE trial, reinforcing the potential of its CELLSEARCH Circulating Tumor Cell (CTC) enumeration system as a predictive biomarker for guiding treatment escalation in hormone receptor-positive, HER2-negative metastatic breast cancer. Published in Clinical Cancer Research, the findings suggest that CTC counts in blood samples could

Read More
Representative image: Native-read targeted sequencing technologies like dTMS are reshaping genomic research by integrating long-read workflows with high-throughput platforms.
Medical Devices & Diagnostics

Wasatch BioLabs, Agilent to scale native-read targeted sequencing for precision multi-omics

Wasatch BioLabs has announced a co-marketing agreement with Agilent Technologies to expand access to its Direct Targeted Methylation Sequencing (dTMS) platform. The partnership integrates Agilent’s SureSelect and Avida enrichment chemistries with Wasatch BioLabs’ Oxford Nanopore-based native-read workflow, aiming to streamline high-throughput targeted sequencing for research use only (RUO) and translational settings. The announcement marks a

Read More
Medical Devices & Diagnostics

What Pillar Biosciences’ China move means for decentralized oncology diagnostics

Pillar Biosciences has expanded its collaboration with AstraZeneca to bring its next-generation sequencing-based liquid biopsy kits to China, aiming to accelerate localized tumor profiling and broaden access to precision oncology diagnostics. The partnership, which includes Shanghai Zhengu Biological Technology Co., Ltd., is designed to support assay implementation across Chinese hospital laboratories to reduce diagnostic turnaround

Read More
Medical Devices & Diagnostics

Can TrilliumBiO and Oncobit make MRD monitoring standard for uveal melanoma in the U.S.?

TrilliumBiO and Oncobit launch a ctDNA-based monitoring platform for uveal melanoma in the U.S. Learn how this could change rare cancer care in 2026.

Read More
Medical Devices & Diagnostics

Guardant and Gemelli bring precision oncology in-house: What it means for EU care delivery

Guardant Health brings its Guardant360 CDx test to Policlinico Gemelli in Italy. Find out how in-house liquid biopsy could reshape cancer diagnostics in Europe.

Read More